期刊
CANCER RESEARCH
卷 69, 期 17, 页码 7013-7021出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-09-0523
关键词
-
类别
资金
- National Cancer Institute [CA42802, CA97098, CA 100707]
Nuclear factor-kappa B (NF-kappa B) is constitutively activated in diverse human malignancies. The mucin 1 (MUC1) oncoprotein is overexpressed in human carcinomas and, like NF-kappa B, blocks cell death and induces transformation. The present studies show that MUC1 constitutively associates with NF-kappa B p65 in carcinoma cells. The MUC1 COOH-terminal subunit (MUC1-C) cytoplasmic domain binds directly to NF-kappa B p65 and, importantly, blocks the interaction between NF-kappa B p65 and its inhibitor I kappa B alpha.. We show that NF-kappa B p65 and MUC1-C constitutively occupy the promoter of the Bcl-xL gene in carcinoma cells and that MUC1-C contributes to NF-kappa B-mediated transcriptional activation. Studies in nonmalignant epithelial cells show that MUC1-C interacts with NF-kappa B in the response to tumor necrosis factor-alpha stimulation. Moreover, tumor necrosis factor-alpha induces the recruitment of NF-kappa B p65-MUC1-C complexes to NF-kappa B target genes, including the promoter of the MUC1 gene itself. We also show that an inhibitor of MUC1-C oligomerization blocks the interaction with NF-kappa B p65 in vitro and in cells. The MUC1-C inhibitor decreases MUC1-C and NF-kappa B p65 promoter occupancy and expression of NF-kappa B target genes. These findings indicate that MUC1-C is a direct activator of NF-kappa B p65 and that an inhibitor of MUC1 function is effective in blocking activation of the NF-kappa B pathway. [Cancer Res 2009;69(17):7013-21]
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据